Gyre Therapeutics (GYRE) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.12
- Estimate
- -$0.06
- Surprise
- -111.8%
- Revenue (period 2026-06-30)
- $29.1M
- Score at report (before → after)
- 5.7 → 5.8/10
Revenue source: xbrl.
How the report landed
Gyre Therapeutics (GYRE) reported a wider loss than forecast — adjusted EPS of -$0.12 against the -$0.06 estimate (a 111.8% shortfall). TrendMatrix's engine moved from Buy (Wait) (5.7/10) to Sell at 5.8/10 after the report — the engine's score rose despite the miss.
Where TrendMatrix's rating stands now
TrendMatrix currently rates GYRE Sell at 5.2/10.
2 of the last 4 quarters beat the estimate; this quarter's -111.8% surprise compares with a +117.5% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- DATA_ISSUE: analyst_target_implausible (raw $18.67 vs price $6.07 — ratio 3.1×). Rejected, falling back to technical TP.
- Quality below floor (3.6 < 4.0)
- Momentum score 1.7/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $6.07
- Price target
- $7.59
- Stop
- $5.65
- Upside to target
- +25.0%
Risk check: RSI 27 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-10-27 — shown for context, not personalized investment advice.
GYRE at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $643.6M
- P/E (fwd)
- 101.2
- 52-week range
- $5.44–$9.14
- Off 52-week high
- 33.6%
- RSI (14)
- 27
- Volume vs avg
- 0.74×
- Score today
- 5.2/10